Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of MiraLAX in Chronic Constipation
NCT00164125Phase 4Completed
- Sponsor
- Braintree Laboratories
- Start
- Jul 2003
- Primary completion
- Nov 2004
- Modality
- Injectable Hydrogels, Implantable Hydrogels, Biodegradable Polymers
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of polyethylene glycol 3350 in chronic constipation, sponsored by Braintree Laboratories. Primary endpoint: Safety (Adverse events and laboratory testing) at 12 months. Started Jul 2003; status: completed.
02
Drugs
polyethylene glycol 3350
03
Conditions
chronic constipation
Beyond the preview
Go deeper on NCT00164125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00164125.